Please login to the form below

Not currently logged in
Email:
Password:

2seventy bio

This page shows the latest 2seventy bio news and features for those working in and with pharma, biotech and healthcare.

BMS and 2seventy bio announce positive results for multiple myeloma treatment

BMS and 2seventy bio announce positive results for multiple myeloma treatment

Bristol Myers Squibb (BMS) and 2seventy bio – a spin-out of bluebird bio – have announced positive phase 3 trial top-line results for Abecma (idecabtagene vicleucel) as a treatment for relapsed ... Steve Bernstein, chief medical officer, 2seventy bio,

Latest news

  • BMS and 2seventy bio move away from CAR-T programme BMS and 2seventy bio move away from CAR-T programme

    2021. The decision made by BMS and 2seventy bio reinforces that the companies’ hopes are pinned on Abecma, as the drug has been in high demand. ... Both companies said they anticipated between $250m and $300m in Abecma sales in 2021, with profits to be

  • bluebird bio splits to create new oncology firm 2seventy bio bluebird bio splits to create new oncology firm 2seventy bio

    2seventy bio gets the company’s immune-oncology cell therapies products, while bluebird bio will continue its work on severe genetic diseases. ... As announced earlier this year, Cambridge, Massachusetts-based bluebird bio has spun off its oncology

  • bluebird bio provides update on 2seventy bio spin-off bluebird bio provides update on 2seventy bio spin-off

    bluebird bio has announced the filing by 2seventy bio of an updated Registration Statement with the US Securities and Exchange Commission (SEC). ... This reflects bluebird bio’s plans for a spin-off of its oncology programmes and portfolio into

  • bluebird bio gears up for split bluebird bio gears up for split

    The company has filled its coffers with $75m in new funding and hired new leaders to support its split into two separate companies, bluebird bio and 2seventy bio. ... In October, the company will split into two independent, publicly traded companies,

  • Gene therapy company bluebird bio quits Europe Gene therapy company bluebird bio quits Europe

    This is not the first such incident for bluebird bio’s gene therapies. ... The company will continue its planned split into two independent, publicly traded companies – bluebird bio and 2seventy bio – by the end of 2021.

More from news
Approximately 6 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...